Study S000838

Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02001363
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 90
Start: 2013-11
Primary completion: 2016-03
Lead sponsor: Chen Wei Ren, MD
Conditions: Acute Myocardial Infarction
Interventions: DRUG:liraglutide (Novo Nordisk, Bagsværd, Denmark); DRUG:liraglutide placebo (Novo Nordisk)
Results posted: FALSE
Secondary identifiers: OTHER:ChinaPLAGH

Registered primary outcomes

the salvage index measured by cardiac magnetic resonance [3 months after primary percutaneous coronary intervention]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025816	Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials. Huang M, Annals of medicine	2017	Systematic review	PMID 28286967 DOI	cites ClinicalTrials.gov:NCT02001363; registry reference DERIVED:28286967
R0021851	Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction. Chen WR, Circulation. Cardiovascular imaging	2016	Randomized trial	PMID 27940956 DOI	cites ClinicalTrials.gov:NCT02001363; registry reference DERIVED:27940956
R0023502	Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Lønborg J, European heart journal	2012	Randomized trial	PMID 21920963 DOI	registry reference BACKGROUND:21920963
R0020467	A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. Liu H, The Journal of endocrinology	2009	Preclinical	PMID 19136619 DOI	registry reference BACKGROUND:19136619
R0021038	GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Noyan-Ashraf MH, Diabetes	2009	Preclinical	PMID 19151200 DOI	registry reference RESULT:19151200
R0027526	Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Garber A, Lancet (London, England)	2009	Randomized trial	PMID 18819705 DOI	registry reference BACKGROUND:18819705